The Union Health Ministry has issued a fresh notification restricting the manufacture, sale and distribution of all Fixed Dose Combination (FDC) that contain chlorpheniramine maleate and phenylephrine hydrochloride. The label must carry a clear warning: “Fixed Dose Combination shall not be used in children below four years of age.”
Key Developments
- Extension of the 2025 restriction to **all** formulations containing the two ingredients.
- Mandatory display of the age‑specific warning on the label, package insert and promotional material.
- Notification issued under Section 26A of the Drugs and Cosmetics Act.
- Effective from the date of publication in the Official Gazette (2026).
Important Facts
The decision follows recommendations of an expert committee and the Drugs Technical Advisory Board (DTAB). The government highlighted two concerns:
- Children under four are prone to dosing errors and adverse reactions from multi‑ingredient medicines.
- Evidence of significant benefit of these combinations in uncomplicated colds is limited.
Adverse effects noted include marked drowsiness or paradoxical excitability from chlorpheniramine, and altered heart rate or blood pressure from phenylephrine.
Exam Relevance
Understanding this directive helps aspirants in:
- GS2 (Polity): How regulatory bodies (Ministry, DTAB, expert committees) formulate drug‑safety policies.
- GS3 (Health & Economy): Public‑health implications of restricting paediatric medicines and the role of legislation like the Drugs and Cosmetics Act.
- GS4 (Ethics): Ethical considerations in protecting vulnerable groups (children) from unsafe pharmaceuticals.
Way Forward
Manufacturers must redesign product labels and ensure compliance before the next batch release. Healthcare providers should counsel parents about safer alternatives for cough and cold in young children. The Ministry may monitor market compliance through periodic inspections and may consider stricter penalties for violations. Aspirants should track similar regulatory trends, as they often appear in answer‑writing questions on public‑health policy and drug safety.